Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech is set to discuss its third-quarter financial results and recent operational achievements in an upcoming conference call. The company, known for its promising cancer immunotherapy, pelareorep, is advancing towards key registrational studies after receiving fast-track designations from the FDA.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
